This Healthcare REIT Stands Out With 6.3% Yield
With a 6.3% yield, REIT stock HealthPeak Properties is among the highest-paying players in the S&P 500, well above the current 1% average.
DOC - Healthpeak Properties, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$18.43
DETAILS
HIGH:
$21.00
LOW:
$17.00
MEDIAN:
$18.00
CONSENSUS:
$18.43
DOWNSIDE:
7.11%
Stock News
Healthpeak Properties: A Healthy Balance Sheet And Growth Opportunities Outweigh Risk Concerns
Healthpeak Properties earns a buy rating, driven by strong capital allocation and a compelling portfolio mix across Outpatient Medical, Labs, and Senior Housing. DOC trades at ~11x P/FFO with a >6% dividend yield, offering both stability and upside from secular and cyclical trends in its segments. Recent moves—like the Janus Living IPO, opportunistic acquisitions, and disciplined share buybacks—unlock value and enhance capital efficiency.
Healthpeak Properties: Lab Weakness Creates A Major Re-Rating Opportunity
Healthpeak Properties is still a Buy after the recent rally, supported by strong earnings, a robust dividend, and significant re-rating potential. DOC's Q1 2026 beat on FFO and revenue; completed the Janus Living IPO; and executed major acquisitions, reinforcing portfolio value and future growth prospects. With $1.17 billion in cash and a sustainable 6.2% monthly dividend yield (~70.7% payout ratio), DOC's dividend looks safe despite macroeconomic headwinds, leaving room for more buybacks.
Here Are Monday’s Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy’s, and More
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as reports indicate that President Trump declined Iran's counteroffer for peace. This comes after a remarkable Friday, when stocks roared to record highs, driven primarily by a stronger-than-expected April jobs report that eased economic concerns and by a... Here Are Monday's Top Wall Street Analyst Research Calls: Dell Technologies, BioMarin Pharmaceutical, Disney, HubSpot, Klarna, Oklo, Pitney Bowes, Trade Desk, Wendy's, and More
The Overlooked Trend That Could Supercharge REIT Dividends
REITs are undervalued and out-of-favor compared to AI-driven tech stocks, creating a contrarian opportunity. Rising construction costs are constraining new supply, increasing the value and pricing power of existing REIT portfolios. Multiple REITs, including AH REALTY TRUST, Chiron Real Estate, Piedmont Realty Trust, and Healthpeak Properties, report higher replacement costs and favorable re-leasing spreads.
Healthpeak Properties Q1 Earnings Call Highlights
Healthpeak Properties NYSE: DOC reported first-quarter 2026 adjusted funds from operations of $0.45 per share and raised its full-year FFO adjusted guidance after completing several major capital allocation moves, including the IPO of its senior housing business, a joint venture recapitalization with Blackstone and a $100 million stock repurchase.
Healthpeak Properties, Inc. (DOC) Q1 2026 Earnings Call Transcript
Healthpeak Properties, Inc. (DOC) Q1 2026 Earnings Call Transcript
Healthpeak Properties Q1 FFOA Tops Estimates on Steady Leasing Momentum
DOC beats Q1 FFOA estimates as leasing stays strong and Janus Living IPO boosts growth, prompting a higher 2026 outlook.
Healthpeak (DOC) Q1 FFO and Revenues Surpass Estimates
Healthpeak (DOC) came out with quarterly funds from operations (FFO) of $0.45 per share, beating the Zacks Consensus Estimate of $0.43 per share. This compares to FFO of $0.46 per share a year ago.
Healthpeak Properties Raises 2026 Earnings Guidance Following Completion of the Janus Living IPO, Accretive Capital Allocation, and Strong First Quarter 2026 Results
DENVER--(BUSINESS WIRE)--Healthpeak Properties, Inc. (NYSE: DOC), a leading owner, operator, and developer of real estate for healthcare discovery and delivery, today announced results for the quarter ended March 31, 2026. FIRST QUARTER 2026 FINANCIAL PERFORMANCE AND RECENT HIGHLIGHTS Net income of $0.28 per share, Nareit FFO of $0.42 per share, and FFO as Adjusted of $0.45 per share In March 2026, Janus Living, Inc. (NYSE: JAN) ("Janus Living") completed its initial public offering ("IPO") at.
What's in the Cards for Healthpeak Properties This Earnings Season?
DOC heads into Q1 earnings with revenues and FFO per share expected to dip as higher interest expenses and competition weigh.
3 Healthcare Stocks Paying the Highest Dividends in the Sector Right Now
Perrigo sports a forward dividend yield nearing 10%, but this high yield is highly reflective of high uncertainty over the company's future performance. Despite a mixed dividend growth track record, an ongoing catalyst may make Healthpeak Properties appealing to investors focused on capital growth.
Financial Review: DiamondRock Hospitality (NYSE:DRH) & Healthpeak Properties (NYSE:DOC)
DiamondRock Hospitality (NYSE: DRH - Get Free Report) and Healthpeak Properties (NYSE: DOC - Get Free Report) are both finance companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, dividends, valuation and earnings. Profitability This table compares DiamondRock Hospitality and Healthpeak
Evergreen Capital Management LLC Invests $544,000 in Healthpeak Properties, Inc. $DOC
Evergreen Capital Management LLC acquired a new position in shares of Healthpeak Properties, Inc. (NYSE: DOC) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 33,815 shares of the real estate investment trust's stock, valued at approximately $544,000. Other
Advisors Capital Management LLC Acquires 34,929 Shares of Healthpeak Properties, Inc. $DOC
Advisors Capital Management LLC boosted its holdings in shares of Healthpeak Properties, Inc. (NYSE: DOC) by 2.5% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,439,624 shares of the real estate investment trust's stock after purchasing an additional
20 Years on Wall Street Taught Me: Build a Massive Dividend Portfolio With Stocks Under $20
After a 35-year career in the financial industry, including two decades as an institutional stockbroker at Bear Stearns, Lehman Brothers, and Morgan Stanley, I developed an institutional perspective on dividend-focused investing. My tenure at these premier Wall Street firms exposed me to fundamental analysis, credit evaluation, and risk management practices, which directly translate into selecting... 20 Years on Wall Street Taught Me: Build a Massive Dividend Portfolio With Stocks Under $20
DOC or NHI: Which Is the Better Value Stock Right Now?
Investors with an interest in REIT and Equity Trust - Other stocks have likely encountered both Healthpeak (DOC) and National Health Investors (NHI). But which of these two stocks is more attractive to value investors?
Key Reasons to Add Healthpeak Properties Stock to Your Portfolio Now
DOC gains from strong lab demand and rising senior healthcare needs, supported by portfolio repositioning and solid balance sheet strength.
Baillie Gifford & Co. Buys 315,763 Shares of Healthpeak Properties, Inc. $DOC
Baillie Gifford and Co. increased its stake in Healthpeak Properties, Inc. (NYSE: DOC) by 613.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 367,256 shares of the real estate investment trust's stock after purchasing an additional 315,763 shares during the period. Baillie Gifford
Want $5,790 in Passive Income? Invest $30,000 Each Into These 3 High-Yield Dividend Stocks
High-yield dividend stocks offer cash flow with full liquidity, meaning you can add, trim, or exit a position on any trading day.
Price Targets
Healthpeak Properties price target raised to $20 from $18 at Morgan Stanley
$20.00
(was $19.70)
Ronald Kamdem
·
Morgan Stanley
Healthpeak Properties price target raised to $19 from $17 at UBS
$19.00
(was $19.78)
UBS
Healthpeak Properties price target lowered to $18 from $21 at Morgan Stanley
$18.00
(was $15.83)
Morgan Stanley
Healthpeak Properties initiated with a Neutral at UBS
$17.00
(was $17.37)
UBS
Healthpeak Properties price target lowered to $18 from $19 at Wells Fargo
$18.00
(was $16.92)
John Kilichowski
·
Wells Fargo
Healthpeak Properties initiated with a Neutral at Goldman Sachs
$17.00
(was $17.04)
Goldman Sachs
Healthpeak Properties price target lowered to $17 from $20 at Cantor Fitzgerald
$17.00
(was $16.16)
Cantor Fitzgerald
Healthpeak Properties downgraded to Hold from Buy at Jefferies
$17.00
(was $16.66)
Jefferies
Healthpeak Properties price target lowered to $21 from $22 at Evercore ISI
$21.00
(was $16.80)
Evercore ISI
Healthpeak Properties initiated with a Neutral at Cantor Fitzgerald
$20.00
(was $19.15)
Cantor Fitzgerald
Healthpeak Properties price target lowered to $22 from $23 at Evercore ISI
$22.00
(was $18.08)
Evercore ISI
Healthpeak upgraded to Outperform from Market Perform at Raymond James
$20.00
(was $18.25)
Jonathan Hughes
·
Raymond James
Healthpeak Properties price target lowered to $21 from $22 at Morgan Stanley
$21.00
(was $17.75)
Morgan Stanley
Healthpeak Properties price target lowered to $21 from $22 at Baird
$21.00
(was $17.22)
Robert W. Baird
Deutsche upgrades Healthpeak to Buy on improving life sciences sector
$28.00
(was $22.64)
Omotayo Okusanya
·
Deutsche Bank
Healthpeak Properties price target raised to $22 from $20 at Citi
$22.00
(was $21.89)
Nick Joseph
·
Citigroup
Healthpeak Properties Inc (DOC) PT Raised to $24 at Baird
$24.00
(was $21.85)
Wesley Golladay
·
Robert W. Baird
Healthpeak Properties Inc (DOC) PT Raised to $25 at RBC Capital
$25.00
(was $21.85)
Michael Carroll
·
RBC Capital
Wedbush Upgrades Healthpeak Properties Inc (DOC) to Outperform
$22.00
(was $19.17)
Richard Anderson
·
Wedbush
Healthpeak Properties Inc (DOC) PT Raised to $22 at RBC Capital
$22.00
(was $19.34)
Michael Carroll
·
RBC Capital